<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528526</url>
  </required_header>
  <id_info>
    <org_study_id>OXY1A_2014-0374</org_study_id>
    <nct_id>NCT02528526</nct_id>
  </id_info>
  <brief_title>Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm</brief_title>
  <acronym>OXY1A</acronym>
  <official_title>A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe
      and tolerated in patients with primary and secondary hepato-pancreato-biliary and
      gastrointestinal neoplasia as measured by exploring the maximum tolerated dose (MTD). At
      level of MTD, additional patients will be included aimed for assessing the efficacy profile
      in these neoplasia entities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMP OXY111A counteracts hypoxia-induced tumor aggressiveness showing decreased tumor
      burden and increased survival in five different animal solid tumor models both applied as
      monotherapy and increased beneficial effects when followed by standard chemotherapy. The
      unique ability of the IMP counteract hypoxic tumor behaviour along with its non-toxic side
      effects tested both in animals and healthy volunteers is of outmost interest to explore in
      patients with solid tumors.

      The study seeks primarily to determine the safety and tolerability of OXY111A in patients
      with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as
      measured by exploring the MTD in a conservative 3+3 dose escalation schedule. The window for
      DLT assessment is from first dose of study drug until first dose of standard of care
      chemotherapy or 10 days following completion of last dose of study drug (whichever is shorter
      in duration). Additionally, we will assess efficacy of OXY111A on decreasing tumor volume,
      metabolic activity, as well as circulatory tumor and angiogenic markers.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as measured by collection of adverse effects information</measure>
    <time_frame>10 weeks</time_frame>
    <description>Safety variables and patient tolerance as measured by collection of adverse effects information according to Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by FDG-PET scan</measure>
    <time_frame>5 months</time_frame>
    <description>Assessment of tumor response with 18F-FDG PET in FDG-avid tumors using EORTC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by MRI</measure>
    <time_frame>5 months</time_frame>
    <description>Assessment of tumor response with MRI in non-FDG-avid tumors using RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXY111A</intervention_name>
    <description>OXY111A intravenous infusion</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Myo-inositol trispyrophosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study Indication: patients diagnosed for non-resectable hepato-pancreato-biliary or
             gastrointestinal neoplasm

          -  Male and Female patients ≥ 18 years of age

          -  Signed Informed Consent after being informed

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of ≥ 2 at study
             entry.

          -  A life-expectancy of &gt;3 months

          -  Adequate hematologic and renal function

          -  Use of effective contraception (per the institutional standard), if procreative
             potential exists

          -  Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least
             28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with
             an investigational agent or device, or prior radiation therapy (palliative radiation
             therapy is allowed)

          -  Accessible for treatment and follow-up. Patients enrolled in this trial must be
             treated at the participating center

        Exclusion Criteria:

          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or
             allergy to class of drugs or the investigational product

          -  Women who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Alain, Clavien</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Visceral Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Alain Clavien, MD, PhD</last_name>
    <phone>+41 (0)44 255 33 00</phone>
    <email>clavien@access.uzh.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Perparim Limani, MD</last_name>
    <phone>+41 (0)44 255 33 00</phone>
    <email>perparim.limani@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Visceral Surgery</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Alain Clavien, MD, PhD</last_name>
      <phone>+41 (0)44 255 33 00</phone>
      <email>clavien@access.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Perparim Limani, MD</last_name>
      <phone>+41 (0)44 255 33 00</phone>
      <email>perparim.limani@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Panagiotis Samaras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Pestalozzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Jetter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Linecker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolf Graf, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bostjan Humar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henrik Petrowsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Kron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Stupp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.vis.usz.ch</url>
    <description>Department of Surgery, University Hospital Zurich, Switzerland</description>
  </link>
  <link>
    <url>http://www.hpb-center.ch</url>
    <description>Swiss Hepato-Pancreato-Biliary (HPB) Center, University Hospital Zurich, Switzerland</description>
  </link>
  <reference>
    <citation>Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, Marescaux J, Egly JM, Lehn JM, Nicolau C. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats. Chembiochem. 2011 Mar 21;12(5):777-83. doi: 10.1002/cbic.201000619. Epub 2011 Mar 2.</citation>
    <PMID>21370375</PMID>
  </reference>
  <reference>
    <citation>Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, Tufa E, Choquet P, Lehn JM, Nicolau C, Duluc I, Freund JN. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene. 2013 Sep 5;32(36):4313-8. doi: 10.1038/onc.2012.445. Epub 2012 Oct 8.</citation>
    <PMID>23045284</PMID>
  </reference>
  <reference>
    <citation>Kieda C, El Hafny-Rahbi B, Collet G, Lamerant-Fayel N, Grillon C, Guichard A, Dulak J, Jozkowicz A, Kotlinowski J, Fylaktakidou KC, Vidal A, Auzeloux P, Miot-Noirault E, Beloeil JC, Lehn JM, Nicolau C. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J Mol Med (Berl). 2013 Jul;91(7):883-99. doi: 10.1007/s00109-013-0992-6. Epub 2013 Mar 9.</citation>
    <PMID>23471434</PMID>
  </reference>
  <reference>
    <citation>Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.</citation>
    <PMID>24214898</PMID>
  </reference>
  <reference>
    <citation>Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1605-8.</citation>
    <PMID>15745806</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Hepatocellular Cancer</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

